Health Canada has approved the initiation of a Phase I/II clinical trial for ExCellThera’s lead product, ECT-100, for the expansion of hematopoietic stem cells (HSCs). The trial will begin early 2016 and will enroll up to 25 patients who require stem cell transplantation for the treatment of acute myeloid leukemia (AML) and other malignant blood disorders with no suitable donor. The trial will take place at multiple Canadian transplant centres but the lead site will be Maisonneuve-Rosemont Hospital in Montreal.

“Health Canada’s approval of ExCellThera’s first clinical trial is an important milestone for the company,” commented Steven J. Klein, CEO of ExCellThera. “ECT-100 will represent a new therapeutic option for patients requiring stem cell transplantation and who lack a traditional donor. We look forward to obtaining initial clinical data for ECT-100 in 2016.”

Source :

add chat to your website

Get Info Pack

Take the first step to learn about cord blood and cord tissue banking today!


Receive your first year of storage for FREE when you enroll to store cord blood & tissue OR when you enroll to store cord blood only

Copy Promo Code:
'271OFF' for Cord Blood & Tissue
'143OFF' for Cord Blood Only
Copy Promo Code Before You Enroll
Offer ends October 30, 2020
Questions about cord blood and COVID-19? 
Read company statement here >>
Canadian Clinical Trial for Cancer Patients using Stem Cells